Powering Real-World Oncology Data for Chinese Cancer Patients
GenomiCare is an innovative, patient-centered biotech company driven to use real-world oncology data to improve outcomes for Chinese cancer patients. Since 2015, GenomiCare has been guiding thousands of Chinese cancer patients towards precision oncology treatment and disease management through integration of longitudinal patient records across multiple institutions and deep in-house sequencing capabilities.
GenomiCare Biotechnology, based in both China and the United States, leverages GenomiCare’s unique real-world data and expansive clinical network across China, to bring real-world oncology solutions to global pharma and biotech companies seeking real-world market understanding and bring cutting-edge cancer therapeutics to Chinese patients with optimized market access.
John Prista Freshley
Acting Executive Vice President, Head of US Operations
Leading the development of GenomiCare’s global pharma and biotech business, John is a high-energy entrepreneur that has founded, launched, and/or led 10 early-stage life science companies. These include multiple oncology drug development companies and multiple big data genomics platform companies, such as Compendia Bioscience, which he launched as start-up CEO and remained as Chief Business Officer through its acquisition by Life Technologies (now Thermo Fisher) in 2012.
Senior Vice President, COO
Dr. Joe Monforte
Head of Strategic Partnering
Joe brings his two decades of experience in Precision Medicine and a deep background in genomics and genetics to supporting Genomicare strategically and technically. Previously, he has served in the role of Chief Scientific Officer for several companies in diagnostic and therapeutic development. As a partner in Wild Type Advisors, Joe continues to advise and educate a range of companies on strategy and tactics in the transition to a more data-driven approach to healthcare.
Executive Director, Data Intelligence Commercial
Vice President, Data Science & Drug Discovery
Andrew Xiuxuan Zhu (MD, Ph.D.)
- Professor of Medicine, Harvard Medical School
- Director of Jiahui International Cancer Center (JICC), Director of JIH Clinical Research
- Director of Liver Cancer Research, Massachusetts General Hospital
Dr. Andrew X. Zhu is an internationally recognized leader in hepatocellular carcinoma (HCC) and cholangiocarcinoma. Dr. Zhu has served as a principal investigator in many pivotal clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers. As the lead global principal investigator, he managed the pivotal studies which led to the regulatory approval of Pembrolizumab and Ramucirumab in advanced HCC. As a co-principal investigator, he lead the phase III trial of first IDH-1 inhibitor Ivosidenib in cholangiocarcinoma with IDH-1 mutations. Dr. Zhu established the multidisciplinary liver cancer clinic and conference at Massachusetts General Hospital in 2009.
Thomas Brown (MD, MBA)
- Chief Medical Officer, Syapse
- Former Director of the Seattle Swedish Cancer Institute
- Former Vice President of MD Anderson Cancer Center
Dr. Thomas Brown has more than 30 years of extensive experience in the management of tumor centers and has a deep understanding on the development of tumor therapy modalities. Dr. Brown's previous positions include serving as the Executive Director of the US Swedish Cancer Institute, where he was in charge of the operations of five major hospital areas. At the MD Anderson Cancer Center, Dr. Brown served numerous roles, including as Professor of Gastrointestinal Medical Oncology, Head of the Division of Cancer Medicine, and Vice President of International Operations for external projects. Dr. Brown also served as Professor of Medicine and Chief Operating Officer at the University of Arizona, and as a Professor at the Cancer Center of Duke University.
Chen Lieping (MD, Ph.D.)
- Director, Cancer Immunology Program, Yale University
Dr. Lieping Chen is an endowed chair professor at Yale University and director of the Cancer Immunology Program. Dr. Chen established the foundation work for the role of PD-L1/PD-1 pathway in tumor immune escape and implemented the strategy for blocking PD-L1/PD-1 with monoclonal antibodies to perform strategic cancer therapy. This important discovery enabled the development of antibody drugs which were approved for the market in 2014 for broad-spectrum treatment of solid tumors. In 2014, Dr. Chen was awarded the William B. Coley Award, a top honor in cancer immunology circles. In 2016, Dr. Chen was the first Chinese-American scientist to win the AAI-Steinman Award from the prestigious American Association of Immunologists.
He Jianxing (Professor, Ph.D. Supervisor)
- Hospital Director and Chief of Thoracic Surgery
- First Affiliated Hospital of Guangzhou Medical University
With an experience spanning 30 years in the Thoracic Surgery department at First Affiliated Hospital of Guangzhou Medical University, Professor He Jianxing has led his team to finish over 28,000 cases of thoracoscopy and thoracoscopic-assisted minimally-invasive chest surgery. This includes 73 cases of lung transplants, with the longest survival period reaching 11 years, as well as patients as late as the age of 81. He is currently the only expert in China who has successfully carried out a clinical allogeneic tracheal transplant and clinical allogeneic lung transplant.
Lu Shun (MD, Ph.D. Supervisor)
- Director of Shanghai Lung Cancer Clinical Medicine Center
Professor Lu Shun is the Director of the Oncology Department of Shanghai Chest Hospital and is a leading expert in the medical industry in Shanghai. He specializes in the treatment of various common and rare lung diseases, and is at the forefront of the latest developments in lung cancer treatments both in China and overseas, with remarkable achievements in early diagnosis, targeted treatments, and comprehensive treatments for lung cancer.
Wang Jiping (MD, Ph .D.)
- Associate Director of Liver Cancer Surgery, Brigham
- Associate Director of Women's Hospital, Harvard University Medical School
Dr. Jiping Wang specializes in minimally-invasive surgery for malignant gastrointestinal tumors, and has more than ten years of experience in clinical trials for breast cancer and intestinal tumors. With a solid background in biostatistics, he focuses on finding and identifying tumor markers for screening, efficacy assessment and prognosis, and aspires to develop algorithms and scoring systems for guiding tumor clinical studies and practices. Dr. Wang has consecutively won the Excellence Award presented at the ASCO Annual Meeting, in addition to the AACR and ACS Scholar Awards.